TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Function of the transplanted extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10 Meter Walk Test Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Berg Balance Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in left ventricular ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe form of COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Change in adherence to sleep restriction
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: incidence of adhesive intestinal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cerebrovascular oxygen delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebrovascular flow reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood brain barrier permeability surface area product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of constrictive pericarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean C5 concentration required to elicit 5 coughs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total cough (citric acid)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tmax - Time to Reach Maximum Plasma Concentration of Levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ - Area Under the Plasma Concentration-time Curve of Levodopa From Time Zero to Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Suppression of ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of fecal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sleep apnea questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Size of tonsils
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-fatal recurrent infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Daytime blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Experience Grade 3 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and severity of Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With CMV Viral Load Greater than or Equal to (>=) 150 Copies per Milliliter (Copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Allogeneic hematopoietic stem cell transplant-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: functional magnetic resonance imaging of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of bacterial load of H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ratio of GMTs for the 2 different vaccine groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: solicited local reactions at injection site
Endpoint domain: Adverse events/effects
Primary endpoint: solicited systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Best objective confirmed response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of Dorsiflexion Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Isometric peak torque at 0° and 10° of plantar flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of Isokinetic plantar-flexion torque at speed of 30°, 60°, 120°/sec
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of 2 Minute Walk Test (2MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side Effects using ARBOT
Endpoint domain: Adverse events/effects
Primary endpoint: Biomarker profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photoplethysmography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of modified therapeutic decisions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 6β-hydroxy-budesonide urine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirm PCD diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic-associated diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: postoperative laboratory parameters changes for nutrition assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postoperative body composition change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of ocular normal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to attain sustained blood pressure goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of women who attend postnatal clinic within 6-8 weeks postpartum
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of infants tested for HIV by DNA PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Histopathological types of superficial lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Fax to Quit referrals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pain in low back
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inpatient all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: episode of overt hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Absolute Number of Sputum Neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Transition Dyspnea Index (TDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility of Recruitment (Number of contacts)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of Recruitment (eligibility rate)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of Recruitment (enrollment rate)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to Exercise Intervention (session attendance)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adherence to Exercise Intervention (kcal adherence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: QOL Global Health Status Deterioration-free Median Survival
Endpoint domain: Mortality/survival
Primary endpoint: My Decision Quality (MDQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ability to generate sufficient vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of vaccination between day 30 to day 45 after transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of treatment related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of CRS
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of Neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Development of intrauterine growth restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Predictive value of the screening tool to undergo standard anticancer treatment in terms of toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious condition
Endpoint domain: Mortality/survival
Primary endpoint: Plasma concentrations of moxidectin and midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Laxity measured by KT-1000 Arthrometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient's evaluation of his own voice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Doctor's evaluation of the patient's voice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice analysis by a software
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of parental self-efficacy in communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of communicational behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Difficulty Score of Laparoscopic Cholecystectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: perioperative blood lactate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: T-cell dependent humoral immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA <40 c/mL at Week 24-Stage 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA <40 c/mL at Week 24-Stage 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: feasibility of implementing an APA intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain reduction measured by VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment with a 30 percent decrease in SCORAD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: number of patients requiring stent replacements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: % frequency liver toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cerebral metabolic rate of oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of blood sugar reversal to normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression to chronic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concordance of asthma symptom expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left Ventricular End Diastolic Volume Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum TG reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TG/HDL-c ratio reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum cytokines (TNFα and IL-6) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Emergency department utilization rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: post-operative cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of patients achieving PASI75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CMV status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Single-breath Diffusing Capacity for Carbon Monoxide (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of hypotension following spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recruitment and adherence rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Probability of latent tuberculosis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum vasopressin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean Changes in MADRS Total Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Treatment Related Dose Delay or Treatment Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Sufficient Patency for Clinical Access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Patients Achieving Dialysis Access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Patients on Dialysis Using the Arteriovenous Fistula or Has Adequate Access Flow Rate to Allow Dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Biomarkers of inherited cardiovascular conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Days to Return of Bowel Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Medication cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hospital stay cost
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient's knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient's preparedness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ELN-IWG Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematological outcomes
Primary endpoint: Incidence of first RV episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of RV-related utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of diarrhea-related utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Freedom of cold symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Bronchial smooth muscle (BSM) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to fulfill discharge criteria
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Patients Experiencing a Stringent Complete Response (sCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of solicited local and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of adverse events (AE) and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Pertussis specific antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Multidrug resistant bacteria acquisition
Endpoint domain: Adverse events/effects
Primary endpoint: L'Insalata score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: American Shoulder and Elbow Surgery (ASES) Patient Survey score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: collagen-epinephrine closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Yale-Brown Obsessive Compulsive Scale, Child Version (CYBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Penetrance of Dasatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Penetrance of Quercetin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of BMX-001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Adverse events, serious adverse events and dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of delayed language
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response after the First Course of HEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Drop in hemoglobin level by 2g%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Responders to Duspatalin® Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Magnesium AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary Magnesium AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of ANX776
Endpoint domain: Adverse events/effects
Primary endpoint: Serious Adverse Events (SAEAs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of in-hospital procedure success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of use of home-based technologies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Condom Usage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ovarian reserve parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: functional impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Inhalatory Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ability to distinguish between benign and malignant thyroid nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lung Cancer Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With 50% Reduction of Baseline eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinite Time (AUC [0-infinity]) of DTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of DTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half-life (t1/2) of DTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved mask ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number and duration of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: change from baseline to 1, 3, 6 months of CCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Diagnostic severity of social anxiety disorder (ADIS CSR score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Treatment response/non-response (CGI-I ratings of 1-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Standardized Rate of Apheresis Treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cystatin C as indicator of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Cystatin C as indicator of renal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in implant stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in bacterial flora in eyelashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in bacterial flora in conjunctiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Late Outgrowth Endothelial Progenitor Colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Categorization of patients as responders or non-responders to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes